GSK asks European regulator to OK malaria shot

(AP)—Pharma giant GSK said Thursday it is submitting its malaria vaccine for regulatory approval to the European Medicines Agency.

The experimental shot is the most advanced candidate vaccine for malaria but results from previous trials have been disappointing. Research published in 2012 showed the shot only reduced malaria cases by about 30 percent in babies aged six to 12 weeks, the target age for immunization. The vaccine, known as RTS,S, seems to work better in older children but its efficacy faded over time.

In a statement on Thursday, GSK said its vaccine is aimed only for use against the malaria parasite most prevalent in Africa.

There is currently no licensed vaccine for malaria. The is spread by mosquitoes and kills about 650,000 people every year, mostly in Africa.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

GSK to seek green light for malaria vaccine

Oct 08, 2013

British drug maker GlaxoSmithKline (GSK) said on Tuesday it hoped to get the green light for a prototype vaccine against malaria after trials showed it offered children a partial shield against the disease.

Recommended for you

Long wait yet for Ebola vaccine: experts

5 hours ago

It will be months, at least, before a vaccine becomes available to tackle Ebola, experts said Thursday as researchers reported success in early, safety tests with a leading candidate.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.